Inspire Advisors’s Sage Therapeutics SAGE Stock Holding History

Inspire Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,553	Closed	-$919K	–	300
2023 Q2	$919K	Buy	19,553 +1,363	+7%	+$67.8K	0.18%	46
2023 Q1	$763K	Buy	+18,190	New	+$782K	0.18%	49
2022 Q2	–	Sell	-12,425	Closed	-$411K	–	153
2022 Q1	$411K	Buy	+12,425	New	+$467K	0.12%	43

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inspire Advisors's SAGE Position: Q3 2023 in Review

Inspire Advisors sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 19,553 shares — an estimated $919K sold.

Inspire Advisors first reported a position in SAGE in Q1 2022 and held it in 3 quarters. The position peaked at $919K in Q2 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Inspire Advisors reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Inspire Advisors sold 19,553 Sage Therapeutics shares in Q3 2023, an estimated $919K.
Inspire Advisors first reported a position in Sage Therapeutics in Q1 2022 and held it in 3 quarters.
Inspire Advisors's Sage Therapeutics position peaked at $919K in Q2 2023.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Inspire Advisors's 13F filing for Q3 2023, filed 26 Oct 2023.